Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Noack A.) > (2015-2019) > Comparison of Dabig...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04611naa a2200433 4500
001		oai:DiVA.org:uu-307886
003		SwePub
008		161122s2016 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3078862 URI
024	7	a https://doi.org/10.1161/CIRCULATIONAHA.115.0209502 DOI
040		a (SwePub)uu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Ezekowitz, Michael D.u Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.;Cardiovasc Res Fdn, New York, NY USA.4 aut
245	1 0	a Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)
264	1	c 2016
338		a print2 rdacarrier
520		a BACKGROUND: The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113 patients with atrial fibrillation. Those with prosthetic heart valves, significant mitral stenosis, and valvular heart disease (VHD) requiring intervention were excluded. Others with VHD were included. METHODS: This is a post hoc analysis of the RE-LY trial. RESULTS: There were 3950 patients with any VHD: 3101 had mitral regurgitation, 1179 with tricuspid regurgitation, 817 had aortic regurgitation, 471 with aortic stenosis, and 193 with mild mitral stenosis. At baseline, patients with any VHD had more heart failure, coronary disease, renal impairment, and persistent atrial fibrillation. Patients with any VHD had higher rates of major bleeds (hazard ratio [HR], 1.32; 95% confidence interval [CI], 1.16-1.5) but similar stroke or systemic embolism event rates (HR, 1.09; 95% CI, 0.88-1.33). For patients receiving dabigatran 110 mg, major bleed rates were lower than for patients taking warfarin (HR, 0.73; 95% CI, 0.56-0.95 with VHD; HR, 0.84; 95% CI, 0.71-0.99 without VHD), and major bleed rates for dabigatran 150 mg were similar to those for warfarin in patients with VHD (HR, 0.82; 95% CI, 0.64-1.06) or without VHD (HR, 0.98; 95% CI, 0.83-1.15). For dabigatran 150 mg, stroke/systemic embolic event rates were lower compared with warfarin in those with VHD (HR, 0.59; 95% CI, 0.37-0.93) and those without VHD (HR, 0.67; 95% CI, 0.52-0.86), and stroke/systemic embolic event rates were similar for warfarin and dabigatran 110 mg regardless of the presence of VHD (HR, 0.97; 95% CI, 0.65-1.45; and HR, 0.88; 95% CI, 0.70-1.10). Intracranial bleeds and death rates for dabigatran 150 and 110 mg were lower compared with warfarin independently of the presence of VHD. CONCLUSIONS: The presence of any VHD did not influence the comparison of dabigatran with warfarin.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653		a atrial fibrillation
653		a stroke
653		a valvular heart diseases
700	1	a Nagarakanti, Rangadhamu Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA.;Electrophysiol Res Fdn, Warren, NJ USA.4 aut
700	1	a Noack, Herbertu Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.4 aut
700	1	a Brueckmann, Martinau Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.;Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany.4 aut
700	1	a Litherland, Claireu Cardiovasc Res Fdn, New York, NY USA.4 aut
700	1	a Jacobs, Marku Albert Einstein Coll Med, New York, NY USA.4 aut
700	1	a Clemens, Andreasu Univ Med Ctr Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany.4 aut
700	1	a Reilly, Paul A.u Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.4 aut
700	1	a Connolly, Stuart J.u McMaster Univ, Hamilton, ON, Canada.4 aut
700	1	a Yusuf, Salimu McMaster Univ, Hamilton, ON, Canada.4 aut
700	1	a Wallentin, Larsu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall
710	2	a Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.;Cardiovasc Res Fdn, New York, NY USA.b Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA.;Electrophysiol Res Fdn, Warren, NJ USA.4 org
773	0	t Circulationg 134:8, s. 589-598q 134:8<589-598x 0009-7322x 1524-4539
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-307886
856	4 8	u https://doi.org/10.1161/CIRCULATIONAHA.115.020950

Hitta via bibliotek

Circulation (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Ezekowitz, Micha ...; Nagarakanti, Ran ...; Noack, Herbert; Brueckmann, Mart ...; Litherland, Clai ...; Jacobs, Mark; visa fler...; Clemens, Andreas; Reilly, Paul A.; Connolly, Stuart ...; Yusuf, Salim; Wallentin, Lars; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kardiologi

Artiklar i publikationen: Circulation

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se